Background: Previousinternationalconsensusstatementsprovidedgeneralpolicies
| INTRODUCTION
The Asia-Pacific Gastric Cancer ConsensusConferencehasprovidedtheguidelinesongastriccancer prevention. 7 TheTorontoConsensusrecentlyreporteditsrecommendations for treatment of H. pylori infection. 8 The prevalence of clarithromycin resistance is lower than 15% in most regions ofTaiwan.
63,69
A RCTwith a crossover design confirmed clarithromycin triple therapy was more effective than levofloxacin triple therapy as a first-line treatment for H. pylori infection inTaiwan. 69 Moreover,thisstudyalsoshowedthatuseofclarithromycintripletherapyasafirst-linetreatmentandlevofloxacintripletherapyasasecondlinetreatmentachievedahigheroveralleradicationratethanthereverse sequence. 69 Inagreement,alarge-scalemeta-analysisshowedthatlevofloxacintripletherapywasnotsuperiortoclarithromycintripletherapy asafirst-linetreatment. 61 Accordingly,clarithromycintripletherapyremainsthefirst-linetreatmentinTaiwanandinothercountriesinwhich theclarithromycinresistancerateisbelow15%.
Anothermeta-analysisofRCTsshowedthatbismuthquadrupletherapywasnotsuperiortoclarithromycintripletherapywhentheseregimens were given for the same duration. 70, 71 However, a prolonged bismuth quadrupletherapy(10days)couldbesuperiortothestandard7-daytripleclarithromycintherapyinregionswithclarithromycinresistancerates above15%. 60, 72 Liouetal.recentlyshowedthata10-daybismuthquadrupletherapywassuperiorto14-daytripletherapyinTaiwan. AstudyinTaiwanreportedthata7-dayconcomitanttherapywassuperiortoa7-daytripletherapy.
76
Arandomizedtrialalsoshowedthat 14-day sequential therapy (but not a 10-day sequential therapy)was superior to 14-day triple therapy. 63, 77 Additional research indicated thathybridandreversehybridtherapieswerehighlyeffectivefirst-line treatments. 66, 78 Severaltrialsshowedthat14-dayconcomitantorhybridtherapieswerelessaffectedbyclarithromycinresistanceandareeffectivealternativestobismuthquadrupletherapyinregionswithhigh clarithromycin resistance. 62, 66, [77] [78] [79] Another randomized trial showed thata10-daybismuthquadrupletherapy(butnota10-dayconcomitanttherapy)wassuperiortoa14-daytripletherapy. 73 Takentogether, The secondary resistance to clarithromycin and levofloxacin is high in patients who failed regimens containing these antibiotics. 57, 92 Accordingly, the reuse of clarithromycin and levofloxacin empirically shouldbeavoided.
Statement II-9: Therapy guided by susceptibilitytesting is recommended for patients who fail two or moreeradicationtherapies.
(Evidencelevel:4,Agreement:92%,
Susceptibility-guidedtherapyismoreeffectivethanempiricaltherapyasafirst-linetreatment. 93 Morespecifically,twocaseseriesshowed theeradicationrateofsusceptibility-guidedtherapyrangedfrom36% to91%. 94, 95 However,susceptibilitytestingisexpensiveandnotwidely available.Mutationsin23SrRNAcorrelatepositivelywithclarithromy-cin resistance and negatively with the efficacy of clarithromycin regimens, andmutations ingyraseAcorrelate positivelywith levofloxacin resistanceandnegativelywiththeefficacyoflevofloxacinregimens. 96 In
Taiwan,apilotstudyshowedthatgenotyperesistance-guidedtherapy achievedan80%eradicationrateasathird-linetreatment. 
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